# Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid

> **NCT00729924** · PHASE2,PHASE3 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 40 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT00729924
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-02
- **Final completion:** 2011-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729924, "Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*